×
About 2,375 results

ALLMedicine™ Hypophosphatemia Center

Research & Reviews  726 results

Risk factors for and effects of persistent and severe hypophosphatemia following ferric...
https://doi.org/10.1210/clinem/dgab852
The Journal of Clinical Endocrinology and Metabolism; Schaefer B, Zoller H et. al.

Dec 2nd, 2021 - Hypophosphatemia, osteomalacia and fractures are complications of certain intravenous iron formulations. To investigate risk factors for incident, severe and persistent hypophosphatemia, and associated alterations in bone and mineral biomarkers fo...

A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomi...
https://doi.org/10.1080/10428194.2021.2005044
Leukemia & Lymphoma; Yashar D, Spektor TM et. al.

Nov 26th, 2021 - High-risk multiple myeloma (MM) continues to have a poor prognosis and remains a therapeutic challenge. This phase 2 study evaluated the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib, and low-dose dexamethasone fo...

Study of People With Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2)
https://clinicaltrials.gov/ct2/show/NCT03478839

Nov 24th, 2021 - This is a natural history study of patients with Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2). GACI is an ultra-rare disorder with an estimated birth prevalence of around 1 in ...

Favorable effects of burosumab on tumor-induced osteomalacia caused by an undetectable ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601343
Medicine Oe Y, Kameda H et. al.

Nov 20th, 2021 - Tumor-induced osteomalacia (TIO) is curable by tumor resection, but detection of the tumor can be challenging. Overproduction of fibroblast growth factor 23 (FGF23) by the tumor causes hypophosphatemia and consequently induces inappropriate bone t...

see more →

Drugs  86 results see all →

Clinicaltrials.gov  27 results

Study of People With Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2)
https://clinicaltrials.gov/ct2/show/NCT03478839

Nov 24th, 2021 - This is a natural history study of patients with Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2). GACI is an ultra-rare disorder with an estimated birth prevalence of around 1 in ...

Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH
https://clinicaltrials.gov/ct2/show/NCT03920072

Sep 1st, 2021 - XLH is a rare, genetic disorder that is serious, chronically debilitating and represents an unmet medical need. XLH is the most common inherited form of rickets and the most common inherited defect in renal tubular phosphate transport. XLH is tran...

Registry for Patients With X-Linked Hypophosphatemia
https://clinicaltrials.gov/ct2/show/NCT03193476

Aug 16th, 2021 - Methodology This is an international, multicentre, prospective, non-interventional, observational Registry of patients with X-Linked hypophosphatemia (XLH). The objectives of this XLH Registry is to collect natural history data of XLH to character...

Study of the Inappropriate Secretion of FGF23 in Patients Followed in Hospital in a Context of Hypophosphatemia
https://clinicaltrials.gov/ct2/show/NCT04846647

May 20th, 2021 - To date, even if the incidence of FGF23-secreting tumours seems rare, no precise bibliographical data is available in the scientific literature. Future studies will have to address this issue in order not to underestimate the frequency of this com...

Prevention of Spontaneous Dental Abscesses in Children With X-linked Hypophosphatemia : a RCT
https://clinicaltrials.gov/ct2/show/NCT04872907

May 5th, 2021 - X-linked hypophosphatemia (XLH) is a vitamin D-resistant familial rickets resulting from a mutation of the PHEX gene. One of the major clinical disorders is dental pulp necrosis, which results in "spontaneous" dental abscesses not related to cario...

see more →

News  111 results

Sacituzumab Govitecan Approved in Europe for Second-Line Metastatic TNBC
https://www.onclive.com/view/sacituzumab-govitecan-approved-in-europe-for-second-line-metastatic-tnbc

Nov 23rd, 2021 - The European Commission has granted marketing authorization for sacituzumab govitecan-hziy (Trodelvy) for use as a monotherapy in the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have previou...

Tidutamab Shows Early Tolerability, Active Immune Profile in Advanced Neuroendocrine Tumors
https://www.onclive.com/view/tidutamab-shows-early-tolerability-active-immune-profile-in-advanced-neuroendocrine-tumors

Nov 15th, 2021 - Tidutamab (previously XmAb18087) was found to be well tolerated with a best overall response of stable disease in patients with advanced, well-differentiated neuroendocrine tumors (NETs) of pancreatic, gastrointestinal (GI), lung and undetermined ...

Infigratinib Represents New Option for FGFR2+ Cholangiocarcinoma, as Efforts Shift to Target Other FGFR Alterations
https://www.onclive.com/view/infigratinib-represents-new-option-for-fgfr2-cholangiocarcinoma-as-efforts-shift-to-target-other-fgfr-alterations

Nov 9th, 2021 - Infigratinib (Truseltiq) represents a strong option for previously treated patients with locally advanced or metastatic cholangiocarcinoma whose tumors harbor FGFR2 fusions or rearrangements, according to Sameek Roychowdhury, MD, PhD, who added th...

X-Linked Hypophosphatemia Exacts Early, High Toll on Musculoskeletal System
https://www.medscape.com/viewarticle/962020

Nov 2nd, 2021 - NEW YORK (Reuters Health) - Adults with X-linked hypophosphatemia (XLH) have high rates of musculoskeletal problems that start as early as age 20 years and gradually accumulate over the years, a new analysis confirms. XLH is a rare inherited disor...

Nivolumab Followed by TIL Therapy Shows Early Safety, Clinical Activity in Metastatic NSCLC
https://www.onclive.com/view/nivolumab-followed-by-til-therapy-shows-early-safety-clinical-activity-in-metastatic-nsclc

Oct 6th, 2021 - Nivolumab (Opdivo) followed by treatment with tumor-infiltrating lymphocytes (TILs) was generally safe and found to have clinical benefit in patients with metastatic non–small cell lung cancer (NSCLC), according to data from a phase 1 trial (NCT03...

see more →